Matthew K. Fust - Nov 1, 2021 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
Director
Signature
/s/ Marc Wilson, as attorney-in-fact
Stock symbol
CRNX
Transactions as of
Nov 1, 2021
Transactions value $
-$211,225
Form type
4
Date filed
11/3/2021, 04:55 PM
Previous filing
Sep 9, 2021
Next filing
Nov 5, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Options Exercise $17.1K +8.95K +71.43% $1.91* 21.5K Nov 1, 2021 Direct F1
transaction CRNX Common Stock Sale -$228K -8.95K -41.67% $25.50 12.5K Nov 1, 2021 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRNX Non-qualified stock option (Right to Buy) Options Exercise $0 -8.95K -42.54% $0.00 12.1K Nov 1, 2021 Common stock 8.95K $1.91 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.
F2 Stock option granted March 17, 2018 with one-third vesting on the first anniversary of the grant date and the remainder vesting in a series of twenty-four (24) successive equal monthly installments thereafter.